We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > fostemsavir

News List

ViiV’s Rukobia receives marketing authorisation in Europe for HIV treatment pharmaceutical-technology
February 10, 2021
GlaxoSmithKline’s (GSK) ViiV Healthcare has announced the European Marketing Authorisation of its Rukobia (fostemsavir) 600mg extended-release tablets for use in combination with antiretroviral (ARV) therapies for treating adults with ...
ViiV Healthcare seeks EMA approval for HIV-1 drug candidate fostemsavir pharmaceutical-business-review
January 15, 2020
ViiV Healthcare has completed a regulatory filing in Europe seeking the approval for fostemsavir for the treatment of HIV-1 infection in adult patients having limited treatment options.
ViiV Healthcare seeks FDA approval for fostemsavir to treat HIV-1 infection pharmaceutical-business-review
December 11, 2019
ViiV Healthcare is seeking approval from the US Food and Drug Administration (FDA) for its fostemsavir to treat HIV-1 infection.